Literature DB >> 32651662

68Ga-FAPi-46 diffuse bilateral breast uptake in a patient with cervical cancer after hormonal stimulation.

Ida Sonni1, Stephanie Lee-Felker2, Sanaz Memarzadeh3,4,5,6, Molly M Quinn3, Christine E Mona7, Katharina Lückerath7, Johannes Czernin7,8,9, Jeremie Calais7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32651662     DOI： 10.1007/s00259-020-04947-z

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  3 in total

1.  Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers.

Authors:  P Garin-Chesa; L J Old; W J Rettig
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

2.  Estrogen-mediated activation of fibroblasts and its effects on the fibroid cell proliferation.

Authors:  Ning Luo; Qiyu Guan; Lihua Zheng; Xiaoyan Qu; Hong Dai; Zhongping Cheng
Journal:  Transl Res       Date:  2013-11-20       Impact factor: 7.012

3.  Stromal fibroblasts from the interface zone of human breast carcinomas induce an epithelial-mesenchymal transition-like state in breast cancer cells in vitro.

Authors:  Ming-Qing Gao; Baek Gil Kim; Suki Kang; Yoon Pyo Choi; Hangran Park; Kyu Sub Kang; Nam Hoon Cho
Journal:  J Cell Sci       Date:  2010-09-14       Impact factor: 5.285
  3 in total
  5 in total

1.  68Ga-FAPI-04 PET/CT, a new step in breast cancer imaging: a comparative pilot study with the 18F-FDG PET/CT.

Authors:  Halil Kömek; Canan Can; Yunus Güzel; Zeynep Oruç; Cihan Gündoğan; Özgen Ahmet Yildirim; İhsan Kaplan; Erkan Erdur; Mehmet Serdar Yıldırım; Bahri Çakabay
Journal:  Ann Nucl Med       Date:  2021-05-02       Impact factor: 2.668

2.  Superiority of 68Ga-FAPI PET/CT scan in detecting additional lesions compared to 18FDG PET/CT scan in breast cancer.

Authors:  Umut Elboga; Ertan Sahin; Tulay Kus; Yusuf Burak Cayirli; Gokmen Aktas; Evren Uzun; Havva Yesil Cinkir; Fatih Teker; Ozlem Nuray Sever; Alper Aytekin; Latif Yilmaz; Aydin Aytekin; Ufuk Cimen; Vuslat Mumcu; Benan Kilbas; Y Zeki Çelen
Journal:  Ann Nucl Med       Date:  2021-08-26       Impact factor: 2.668

Review 3.  Clinical summary of fibroblast activation protein inhibitor-based radiopharmaceuticals: cancer and beyond.

Authors:  Mengting Li; Muhsin H Younis; Yongxue Zhang; Weibo Cai; Xiaoli Lan
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-01-31       Impact factor: 10.057

Review 4.  Clinical results of fibroblast activation protein (FAP) specific PET for non-malignant indications: systematic review.

Authors:  Paul Windisch; Daniel R Zwahlen; Frederik L Giesel; Eberhard Scholz; Patrick Lugenbiel; Jürgen Debus; Uwe Haberkorn; Sebastian Adeberg
Journal:  EJNMMI Res       Date:  2021-02-19       Impact factor: 3.138

5.  Could Fibroblast Activation Protein (FAP)-Specific Radioligands Be Considered as Pan-Tumor Agents?

Authors:  Hessamoddin Roustaei; Zahra Kiamanesh; Emran Askari; Ramin Sadeghi; Kamran Aryana; Giorgio Treglia
Journal:  Contrast Media Mol Imaging       Date:  2022-02-22       Impact factor: 3.161
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.